News
It is a small molecule, ATP-competitive kinase inhibitor. The compound is characterized by an exquisite selectivity for its target. This target has been validated with KO-mice in models of lung and kidney fibrosis. FIB992-079 doesn’t […]
Networking, partnering and debating critical issues: BioEurope: Basel, Switzerland, March 2023 BioEquity Dublin, Ireland May 2023 –Presenter Bio International Convention, Boston, MA, June 202 Jeffries Global Healthcare Conference, New York, NY June 2023
Oct 1, 2021 For Immediate Release – Fibrocor Therapeutics Inc, a precision medicine company developing first in class drugs for IPF and other fibrotic diseases, is participating at the upcoming Piper Sandler Lung Day conference […]
Fibrocor is pleased to be presenting at TSX Life Sciences Investor Day
TORONTO, CANADA / ACCESSWIRE / OCTOBER 27, 2020 – Fibrocor Therapeutics Inc. (“Fibrocor” or “the Company”), a privately held developer of de novo therapeutics to treat Fibrosis, announced today the appointment of industry veteran William […]
Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos […]
Mechelen, Belgium; December 2018, 22.01 CET – Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel target for idiopathic pulmonary […]
